| Identification | Back Directory | [Name]
L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- | [CAS]
932744-62-2 | [Synonyms]
MB-VC-MGBA L-Ornithinamide, N-[2-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxobutyl]amino]ethyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[[[2-[[(1S)-1-(chloromethyl)-1,2-dihydro-5-[[(4-methyl-1-piperazinyl)carbonyl]oxy]-3H-benz[e]indol-3-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]phenyl]- | [Molecular Formula]
C56H65ClN12O10 | [MOL File]
932744-62-2.mol | [Molecular Weight]
1101.64 |
| Hazard Information | Back Directory | [Uses]
MB-VC-MGBA is a agent-linker conjugate for ADC with potent antitumor activity by using MGBA (minor-groove-binding DNA-alkylating agent), linked via the ADC linker MB-VC[1]. | [IC 50]
Duocarmycins | [References]
[1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
|
|